Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event ending it. Let's examine the transcript. Key points: Ilan discusses ICP, pathology services, IV-Cell, HemeScreen. He mentions that pathology services are growing, and that they are investing in sales force. He says "we will continue to invest and further develop into ICP" and "we will continue to build sales and commercialization channels". That's general investment. Carl Iberger discusses financial challenges: "we are still burning cash; however, we are closing the gap as sales continue to grow and we've developed new revenue streams". He mentions "we have considerable investment expenses to grow the business, R&D and the sales force are priorities." He also mentions "we are challenged from a leverage balance sheet" and "we still need to manage cash flow to grow and deliver on our strategy." He says "In the near-term, the company will look to secure additional funding through a combination of debt financing and equity." That suggests they need to raise money, not that they are already paying for something with a specific near-dated event. Is there a specific waiting period? They talk about expanding in-house molecular testing capabilities that will eliminate outsourcing. That is a cost-saving measure, but not a waiting period for a specific event. They talk about HemeScreen launched two weeks ago, already receiving orders. That's already earning. The question asks: "does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET — that is, does management convey that the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet, AND that the end of that waiting period is a specific, near-dated event the company can already see and is already working toward?" Management does not describe a specific waiting period with a near-dated event. They talk about general growth investments, but they also mention they need to secure additional funding. They don't say "we are paying for X and it will start earning on date Y". They talk about revenue growth in pathology, but that's already happening.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.